CN1270043A - Medicine for treating hemicrania - Google Patents
Medicine for treating hemicrania Download PDFInfo
- Publication number
- CN1270043A CN1270043A CN 00110854 CN00110854A CN1270043A CN 1270043 A CN1270043 A CN 1270043A CN 00110854 CN00110854 CN 00110854 CN 00110854 A CN00110854 A CN 00110854A CN 1270043 A CN1270043 A CN 1270043A
- Authority
- CN
- China
- Prior art keywords
- radix
- rhizoma
- medicine
- treatment according
- migrainous medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 49
- 206010019233 Headaches Diseases 0.000 title abstract description 22
- 229940079593 drug Drugs 0.000 title description 10
- 241000628997 Flos Species 0.000 claims description 8
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 6
- 241001643642 Viticis Species 0.000 claims description 5
- 239000009636 Huang Qi Substances 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 235000003826 Artemisia Nutrition 0.000 claims description 2
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims description 2
- 240000006891 Artemisia vulgaris Species 0.000 claims description 2
- 241000756943 Codonopsis Species 0.000 claims description 2
- 244000236658 Paeonia lactiflora Species 0.000 claims description 2
- 235000008598 Paeonia lactiflora Nutrition 0.000 claims description 2
- 241000951376 Schizonepeta tenuifolia Species 0.000 claims description 2
- 235000009052 artemisia Nutrition 0.000 claims description 2
- 239000009670 cang er zi wan Substances 0.000 claims description 2
- 239000010135 fructus aurantii immaturus Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 29
- 230000008901 benefit Effects 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract description 2
- 241000213006 Angelica dahurica Species 0.000 abstract 2
- 241001254604 Angelica pubescens Species 0.000 abstract 1
- 241000132012 Atractylodes Species 0.000 abstract 1
- 231100000869 headache Toxicity 0.000 description 20
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 208000019695 Migraine disease Diseases 0.000 description 10
- 208000002193 Pain Diseases 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 206010027599 migraine Diseases 0.000 description 7
- 230000036407 pain Effects 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 239000000341 volatile oil Substances 0.000 description 4
- 206010010904 Convulsion Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 102000010909 Monoamine Oxidase Human genes 0.000 description 3
- 108010062431 Monoamine oxidase Proteins 0.000 description 3
- 230000036592 analgesia Effects 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 239000000812 cholinergic antagonist Substances 0.000 description 3
- 230000036461 convulsion Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000007917 intracranial administration Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000005057 refrigeration Methods 0.000 description 3
- 230000002048 spasmolytic effect Effects 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 208000001140 Night Blindness Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- OFKDAAIKGIBASY-VFGNJEKYSA-N ergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C3=CC=CC4=NC=C([C]34)C2)=C1)C)C1=CC=CC=C1 OFKDAAIKGIBASY-VFGNJEKYSA-N 0.000 description 2
- 229960004943 ergotamine Drugs 0.000 description 2
- XCGSFFUVFURLIX-UHFFFAOYSA-N ergotaminine Natural products C1=C(C=2C=CC=C3NC=C(C=23)C2)C2N(C)CC1C(=O)NC(C(N12)=O)(C)OC1(O)C1CCCN1C(=O)C2CC1=CC=CC=C1 XCGSFFUVFURLIX-UHFFFAOYSA-N 0.000 description 2
- 210000001061 forehead Anatomy 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 1
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 1
- WMBOCUXXNSOQHM-FLIBITNWSA-N (Z)-3-butylidenephthalide Chemical compound C1=CC=C2C(=C/CCC)/OC(=O)C2=C1 WMBOCUXXNSOQHM-FLIBITNWSA-N 0.000 description 1
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 201000009487 Amblyopia Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- TYPSVDGIQAOBAD-DZGCQCFKSA-N Atractylone Chemical compound C([C@]1(C)C2)CCC(=C)[C@@H]1CC1=C2OC=C1C TYPSVDGIQAOBAD-DZGCQCFKSA-N 0.000 description 1
- 229930192334 Auxin Natural products 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 241000589562 Brucella Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 1
- 241000212948 Cnidium Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- -1 Coumarins chemical compound Chemical class 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000027219 Deficiency disease Diseases 0.000 description 1
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 101710106745 Histamine oxidase Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000007316 Neurocysticercosis Diseases 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229940118377 Vitamin antagonist Drugs 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002363 auxin Substances 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 208000013219 diaphoresis Diseases 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 1
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- WMBOCUXXNSOQHM-UHFFFAOYSA-N n-butylidenephthalide Natural products C1=CC=C2C(=CCCC)OC(=O)C2=C1 WMBOCUXXNSOQHM-UHFFFAOYSA-N 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 208000005368 osteomalacia Diseases 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 210000001034 respiratory center Anatomy 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 235000015500 sitosterol Nutrition 0.000 description 1
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 150000005856 steroid saponins Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 210000001186 vagus nerve Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000002550 vasoactive agent Substances 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 230000001457 vasomotor Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
A Chinese medicine for treating hemicrania is prepared from 14 Chinese-medicinal materials including Chinese angelica root,Chuan-xiong rhizome, dahurian angelica root, pubescent angelica root, atractylodes rhizome, etc. Its advantages are high curative effect, high cure rate up to 65%, high effective rate up to 98%.
Description
The invention belongs to and take Chinese herbal medicine in a kind of, particularly a kind ofly be used for the treatment of migrainous medicine.
Headache is a subjective symptoms, be that the intracranial other factor is upset to pain sensation sensitive structure and a kind of very common clinically disease of causing, common factor is inflammation, cranium portion wound, cerebrovascular disease, intracranial tumor, cerebral cysticercosis, N systemic-function obstacle, diseases of the five sense organs etc., above-mentioned factor can make the outer tremulous pulse of intracranial meninges, tremulous pulse, vein and cranium, nervi trigeminus, nervus glossopharyngeus, vagus nerve, the neural irriate of strength 1-3, cause blood vessel to expand and, convulsion is twin, move and fully recover from an illness or be subjected to tractive, and produce headache.Its sickness rate women is higher than the male.Show that in conjunction with data at home and abroad the sick rate of women is 12.9-17.6%. The male is 3.4-6.1%, so sickness rate is higher, causes spirit and sensual very big misery to the patient, is a kind of comparatively obstinate disease.
Doctor trained in Western medicine generally adopts prostate inhibitor or vasoconstrictor Drug therapy at present, as aspirin, indometacin or Ergotamine, two hydrogen wheat show amine etc., because medicines such as Ergota class have certain side effect to human body, and have recessiveness, human body is caused certain injury.Simultaneously can only alleviate the headache symptom temporarily, not reach the purpose of radical cure.
Dialectical the executing of general employing acupuncture, massage, external application and endo-medicine controlled on the traditional Chinese medical science, and certain curative effect is arranged.But curative effect is relatively poor, and cure rate is low.
The object of the present invention is to provide and a kind ofly can effectively treat migrainous medicine, for oral administrationly use, cure rate is higher.
The present invention is achieved in that
The migrainous medicine of a kind of treatment is characterized in that it is the medicament that is made by the following weight proportion raw material: Radix Angelicae Sinensis 3--5, Rhizoma Chuanxiong 3--5, Radix Angelicae Dahuricae 3--5, Rhizoma alpiniae chinensis 3--5, Radix Angelicae Pubescentis 3--5, Rhizoma Atractylodis 3--5, Radix Saposhnikoviae 3--5, Radix Ophiopogonis 3--5, Radix Scutellariae 4--6, Fructus Viticis 2--4, Flos Chrysanthemi 2--4, Herba Asari 1--3, Radix Glycyrrhizae 1--3, Rhizoma Zingiberis Recens 1--2.
The present invention is that pure Chinese medicine is made, and modern pharmacological research proves:
Radix Angelicae Sinensis contains volatile oil approximately, and composition is positive butylidenephthalide, and the fragrance that the tool Radix Angelicae Sinensis is intrinsic and just contains-acyl benzene o-carboxylic acid, sitosterol, vitamin B12, vitamin E, nicotinic acid, sucrose.Have excited uterus muscle, make and shrink the effect of strengthening, experimental results show that the uterus effect is had the amphicheirality.The effect of vitamin antagonist E deficiency disease is arranged.Can reduce the irritability of cardiac muscle.The experimental performance atherosclerosis there is certain curative effect.
Rhizoma Chuanxiong contains volatile oil, and composition is Rhizoma Chuanxiong lactone, cnidium acid, Rhizoma Chuanxiong acid esters and alcohol thing in the oil, and being used for the part has stimulation, for excited effects such as oblongata vasomotor center, respiratory centers, brain is then benumbed.
The Radix Angelicae Dahuricae contains the Coumarins chemical compound, and the expansion artery effect is arranged, and energy excitor nerve maincenter can strengthen breathing, make increased blood pressure in a small amount.Can cause intermittent convulsions in a large number.
Rhizoma alpiniae chinensis contains volatile oil, and brucella is had inhibitory action.
Radix Angelicae Pubescentis contains agedoite etc., and analgesia, spasmolytic, syngignoscism are arranged, and blood vessel dilating is arranged, the effect that brings high blood pressure down.
Rhizoma Atractylodis, Main Ingredients and Appearance are atractylol, and are effective to nyctalopia, osteomalacia, Keratoderma disease, and hypoglycemic activity is arranged.
Radix Saposhnikoviae contains volatile oil and mannitol, aldehydes matter, and polysaccharide and organic acid mainly contain refrigeration function.
Contain multiple steroid saponin Radix Ophiopogonis, and Staphylococcus albus, bacillus subtilis, escherichia coli and Bacillus typhi are had inhibitory action.
Radix Scutellariae contains five kinds of flavone compositions, and its decoct has inhibitory action to alpha streptococcus, streptococcus pneumoniae etc.Experimental heating there is refrigeration function.Also have effects such as blood pressure lowering, diuresis, function of gallbladder promoting, the blood glucose that protects the liver, raises.
Fructus Viticis contains pale reddish brown male centautin, alkaloid, and analgesic activity is arranged, and is used for nervous headache, myalgia, and regulate body temperature maincenter antipyretic effect is arranged, and nyctalopia and the amblyopia deficient to Liver and kidney have certain curative effect.
Flos Chrysanthemi contains Flos Chrysanthemi glycosides, vitamin B1, volatilization wet goods, and refrigeration function is arranged, and water decoction can be treated coronary heart disease, also can be used for treating diseases such as acute binding film inflammation, hypertension.
Herba Asari contains quintessence oil, and a small amount of Herba Asari copper is wherein arranged, and diaphoresis, analgesia and anesthetic action are arranged, and the wet effect of eliminating the phlegm.Clinically headache, lumbago, general pain, toothache there is certain curative effect.
Radix Glycyrrhizae contains glycyrrhizin, and stronger Detoxication is arranged, and to the smooth muscle convulsion is twin mitigation is arranged, and has the effect of antiinflammatory and antiallergic action.
Rhizoma Zingiberis Recens is used to strengthen the associating drug effect of above-mentioned all medicines.
Medicine of the present invention is that pure Chinese medicine is made, have expelling wind and cold, removing damp-heat, invigorate blood circulation exempt from pain, fill blood, the effect of easing the affected liver to relieve pain, better to treatment migraine effect, cure rate reaches 65%, effective percentage reaches 98%.Its comprehensive function is:
1, theory of Chinese medical science is thought, head is mansion, the confluence of all yang-channels of clear sun, the pathological changes of the vital organs of the human body is compiled in head on all, consolidate the invention medicine have dispelling wind pathogens, Yin Yang balancing and smooth clear sun, suppressing the hyperactive liver to relieve the wind syndrome, blood circulation promoting and blood stasis dispelling, enrich blood invigorate blood circulation, circulation of qi promoting, temperature three-way meridian, relieving restlessness calm the nerves, pacify effects such as brain pain relieving.
2, the doctor trained in Western medicine theory is thought, drug ratio science of the present invention also can act on the central nervous system.Have spasmolytic, spasmolytic, analgesia, abirritative effect, but thereby microcirculation improvement.Have and regulate the arteries Zhang Zuoyong that contracts.Promptly arteries there is tangible relaxation effect, and can reduces vascular resistance, cerebral blood flow increasing amount, blood viscosity lowering, the headache symptom that the hypoxic-ischemic that causes because of blood supply insufficiency with change causes.
3, suppress hematoblastic accumulative effect.Contain more ADP and ATP and calcium in the migraine disease human blood platelets, also contain materials such as adenine, and migraine disease human blood platelets activity of monoamine oxidase reduces.This prescription can directly be regulated this pathological phenomenon, and it is returned in the physiological range.
4, immunoregulation effect.The antigen-antibody immune complex is higher than 3 times of normal persons in the migraine disease human blood, and this complex can trigger the infringement of tissue, thereby discharges multiple vaso-active substance, as histamine and 5-HT etc.Thereby the immunocompetence of regulating the migraine people is very necessary.Because of contain in the present invention prescription enrich blood invigorate blood circulation, replenishing QI to invigorate the spleen class medicine, make this prescription have this function.
5, participate in the metabolism of carbohydrate and free fatty acid, during migraine, carbohydrate tolerance reduces, and plasma insulin level reduces, blood plasma free fatty acid, glycerol, ketoboidies and auxin level raise, so the participation of expelling wind and removing dampness medicine can directly be regulated this.Variation to prostaglandin, catecholamine, neuropeptide, histamine and monoamine oxidase, MAO also plays certain regulating action in addition.
Clinical drug of the present invention uses the result to show to have following advantage:
1, to select natural plants for use be raw material in the present invention, and each constituent content proportioning science is utilized the comprehensive function of the Chinese medicine of respectively distinguishing the flavor of, and can effectively treat the migraine due to a variety of causes, has no side effect, and cost is low, taking convenience.
2, the present invention is a starting point to keep fit to consolidate, and is aided with expelling wind and cold, the effect of what, strengthening body resistance and dispelling evil, Yin Yang balancing of dispelling of invigorating blood circulation, treating both the principal and secondary aspects of a disease.
3, medicine of the present invention main formula use separately also can be equipped with attached side according to the morbidity of different reasons, different parts, and therapeutic effect is more obvious.
4, the present invention's dose of filling a prescription is extremely light, medication is short and small astute and able, gently to get effect clearly, avoided dose in the past overweight, damage the side effect of gastric qi easily.Be particular about and select YAOJING tight, the smart medicine of little side, power is drawn severe and lingering illness.
5, new and old to all, the far and near headache of the present invention is all effective, short treating period, cure rate height.
The invention will be further described below in conjunction with embodiment.
Embodiment 1, gets Radix Angelicae Sinensis 5 grams, Rhizoma Chuanxiong 5 grams, the Radix Angelicae Dahuricae 5 grams, Rhizoma alpiniae chinensis 5 grams, Radix Angelicae Pubescentis 5 grams, Rhizoma Atractylodis 5 grams, Radix Saposhnikoviae 5 grams, restrain Radix Ophiopogonis 5, Radix Scutellariae 6 grams, Fructus Viticis 4 grams, Flos Chrysanthemi 4 grams, Herba Asari 3 grams, Radix Glycyrrhizae 3 grams, Rhizoma Zingiberis Recens 2 grams are with being decocted in water for oral dose, once a day, 12 days is a course of treatment, can effectively treat the migraine due to a variety of causes.
Embodiment 2, get the Chinese medicine of above-mentioned weight proportion, add each 4 gram of Radix Bupleuri, the Radix Rehmanniae again, Flos Carthami, each 5 gram of Radix Gentianae, instructions of taking with last with, migraine on the left of can effectively treating.
Embodiment 3, get the Chinese medicine of above-mentioned weight proportion, add the Radix Astragali, each 3 gram of Radix Puerariae again, can effectively treat the right side migraine.
Embodiment 4, get the Chinese medicine of above-mentioned weight proportion, add Rhizoma Gastrodiae 2 grams again, and Fructus Crataegi, Fructus Aurantii Immaturus, each 4 gram of the Rhizoma Pinelliae can effectively be treated the forehead supraorbital bone pain.
Embodiment 5, get the Chinese medicine of above-mentioned weight proportion, add Artemisia benzene, each 3 gram of Radix Et Rhizoma Rhei again, can effectively treat insane top pain.
Embodiment 6, get the Chinese medicine of above-mentioned weight proportion, add Fructus Xanthii 5 gram again, and Fructus Chaenomelis, each 3 gram of Schizonepeta tenuifolia Briq can effectively be treated wind and be gone into and have a headache due to the brains.
Embodiment 7, get the Chinese medicine of above-mentioned weight proportion, add the Radix Astragali 6 grams, Radix Codonopsis 6 grams, white peony root 3 grams, the Radix Rehmanniae 4 grams again, and effectively QI and blood two void often have the headache of spontaneous perspiration class.
For the effect of checking medicine of the present invention, carried out following clinical trial in carrier ring clinic, Ji, Yanggu County, Shandong Province so far from 96, test headache patient patient 180 examples altogether, between age 12-70 year, medical history 0.3-32 does not wait.Be divided into two groups at random, wherein take medicine of the present invention for one group, be test group, totally 95 examples; Take Ergotamine and salicylic acid medicine for one group, be matched group, totally 85 examples.12 days is a course of treatment.
Criterion of therapeutical effect is: 1, self-induction headache transference cure, electroencephalogram, brain blood figure check that genus person's normal range is for curing; 2, self-induction headache sx but still send out the author once in a while, and electroencephalogram, brain blood figure inspection are still for unusual but the improver to be arranged before the treatment be effective; 3, after the medication, the pain symptom does not have alleviation or the person of increasing the weight of is invalid.
Curative effect is reported as follows:
1, in the test group, effective 92 examples, healing 80 examples are followed up a case by regular visits to 1-2 and are not had recurrence; Invalid 3 examples.
2, in the matched group, effective 48 examples, healing 17 examples are followed up a case by regular visits to 1-2 and are not had recurrence; Invalid 20 examples.
From above-mentioned test group, randomly draw 6 people, be specially:
Example 1,46 years old, the woman, first visit in 97 years, the main suit was from sensation left side headache in 85 years, and blood pressure reaches 170/90mmHG, takes depressor, but after the blood pressure drops, headache increases the weight of, and with tinnitus.Be diagnosed as and have a headache due to the mass formed by blood stasis, take medicine of the present invention, in 1 week of medication, cure fully.Follow up a case by regular visits to not recurrence in 2 years.
Example 2, man, 40 years old, first visit in 98 years.Began to have a headache before year surplus in the of 10, its postemphasis, outbreak in every month 2-3 time continues a couple of days sometimes, is diagnosed as the headache of forehead and bilateral temple type.Take medicine of the present invention 6 times, transference cure.Follow up a case by regular visits to not recurrence in a year.
Example 3, man, 58 years old, first visit in 98 years was had a headache 15 years.Take medicine of the present invention 13 times, sx, continue to take 5 doses after, cure fully, follow up a case by regular visits to and do not have recurrence.
Example 4, woman, 38 years old, to have a headache 6 surplus moons, light when weighing during performance, painful area is fixing, and it is invalid once to take multiple medicine, increases the weight of recently.Take 12 doses of medicines of the present invention, pain disappears.
Example 5, woman, 16 years old, first visit in 99 years, old headache of readme 2 years is surplus, takes 8 doses of medicines of the present invention, and symptom is eliminated, and follows up a case by regular visits to and does not have recurrence.
Claims (8)
1, the migrainous medicine of a kind of treatment is characterized in that: it is the medicament Radix Angelicae Sinensis 3--5 that is made by the following weight proportion raw material, Rhizoma Chuanxiong 3--5, Radix Angelicae Dahuricae 3--5, Rhizoma alpiniae chinensis 3--5, Radix Angelicae Pubescentis 3--5, Rhizoma Atractylodis 3--5, Radix Saposhnikoviae 3--5, Radix Ophiopogonis 3--5, Radix Scutellariae 4--6, Fructus Viticis 2--4, Flos Chrysanthemi 2--4, Herba Asari 1--3, Radix Glycyrrhizae 1--3, Rhizoma Zingiberis Recens 1--2.
2, the migrainous medicine of treatment according to claim 1 is characterized in that: wherein the weight proportion of each raw material is a Radix Angelicae Sinensis 5, Rhizoma Chuanxiong 5, the Radix Angelicae Dahuricae 5, Rhizoma alpiniae chinensis 5, Radix Angelicae Pubescentis 5, Rhizoma Atractylodis 5, Radix Saposhnikoviae 5, Radix Ophiopogonis 5, Radix Scutellariae 6, Fructus Viticis 4, Flos Chrysanthemi 4, Herba Asari 3, Radix Glycyrrhizae 3, Rhizoma Zingiberis Recens 2.
3, the migrainous medicine of treatment according to claim 1 and 2, it is characterized in that: it also contains Radix Bupleuri, the Radix Rehmanniae, Flos Carthami, Radix Gentianae.
4, the migrainous medicine of treatment according to claim 1 and 2, it is characterized in that: it also contains the Radix Astragali, Radix Puerariae.
5, the migrainous medicine of treatment according to claim 1 and 2, it is characterized in that: it also contains Rhizoma Gastrodiae, Fructus Crataegi, Fructus Aurantii Immaturus, the Rhizoma Pinelliae.
6, the migrainous medicine of treatment according to claim 1 and 2, it is characterized in that: it also contains Artemisia benzene, Radix Et Rhizoma Rhei.
7, the migrainous medicine of treatment according to claim 1 and 2, it is characterized in that: it also contains Fructus Xanthii, Fructus Chaenomelis, Schizonepeta tenuifolia Briq.
8, the migrainous medicine of treatment according to claim 1 and 2, it is characterized in that: it also contains the Radix Astragali, Radix Codonopsis, white peony root, the Radix Rehmanniae.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 00110854 CN1253201C (en) | 2000-01-27 | 2000-01-27 | Medicine for treating hemicrania |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 00110854 CN1253201C (en) | 2000-01-27 | 2000-01-27 | Medicine for treating hemicrania |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1270043A true CN1270043A (en) | 2000-10-18 |
| CN1253201C CN1253201C (en) | 2006-04-26 |
Family
ID=4580816
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 00110854 Expired - Fee Related CN1253201C (en) | 2000-01-27 | 2000-01-27 | Medicine for treating hemicrania |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1253201C (en) |
Cited By (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100345567C (en) * | 2006-01-17 | 2007-10-31 | 常效春 | Medicine for treating functional headache |
| CN101095900B (en) * | 2007-07-10 | 2010-11-10 | 黑龙江省中医研究院 | Sichuan chrysanthemum pain-relieving capsule and method for preparing the same |
| CN102145132A (en) * | 2011-03-13 | 2011-08-10 | 刘秀娥 | Traditional Chinese medicine for treating forehead pain |
| CN101167817B (en) * | 2007-10-20 | 2011-12-07 | 刘衍 | Traditional Chinese medicine for treating migraine |
| CN102342994A (en) * | 2011-10-18 | 2012-02-08 | 文登市口腔医院 | Traditional Chinese medicine for treating trigeminal neuralgia |
| CN102641418A (en) * | 2012-05-14 | 2012-08-22 | 文庆贤 | Medicament for treating migraine |
| CN102727834A (en) * | 2012-07-18 | 2012-10-17 | 南京中医药大学 | Traditional Chinese medicine composition for treating migraine, and preparation method and application thereof |
| CN103263575A (en) * | 2013-06-01 | 2013-08-28 | 周留侠 | Medicine for treating headache and preparation method thereof |
| CN103272126A (en) * | 2013-05-30 | 2013-09-04 | 龙舟 | Traditional Chinese medicine for treating migraine |
| CN103330786A (en) * | 2013-07-11 | 2013-10-02 | 西华大学 | Medicinal composition for treating migraines, and preparation method thereof |
| CN103385933A (en) * | 2013-07-19 | 2013-11-13 | 苏州市天灵中药饮片有限公司 | Catechu-containing traditional Chinese medicine preparation and preparation method thereof |
| CN103585596A (en) * | 2013-10-18 | 2014-02-19 | 程广金 | Traditional Chinese medicine composition for treating migraine |
| CN103611129A (en) * | 2013-11-28 | 2014-03-05 | 秦雅昀 | Traditional Chinese medicine for treating neuropathic headache |
| CN103816367A (en) * | 2014-03-05 | 2014-05-28 | 济南伟传信息技术有限公司 | Traditional Chinese medicine for treating migraine |
| CN103920020A (en) * | 2014-04-15 | 2014-07-16 | 韩世昌 | Traditional Chinese medicine composition for treating headache and preparation method thereof |
| CN104383297A (en) * | 2014-10-30 | 2015-03-04 | 蔡炜 | Medicine for treating migraine |
| CN104435692A (en) * | 2014-12-19 | 2015-03-25 | 徐杨来 | Prescription for treating nerve headache and preparation method thereof |
| CN105233007A (en) * | 2015-10-30 | 2016-01-13 | 王志勇 | Traditional Chinese medicinal composition for treating migraine and preparation method of traditional Chinese medicinal composition |
| CN106511504A (en) * | 2016-12-20 | 2017-03-22 | 刘震 | Chinese patent medicine for conditioning migraine |
| CN107080787A (en) * | 2017-04-28 | 2017-08-22 | 吴冬梅 | Sedation-analgesia dissipates fiery soup |
| CN108096511A (en) * | 2018-01-24 | 2018-06-01 | 刘清 | A kind of Chinese medicine preparation and its manufacturing method of rapid recovery antimigraine |
| CN108159349A (en) * | 2018-01-17 | 2018-06-15 | 王芬 | A kind of Chinese medicine preparation for treating migraine and preparation method thereof |
| CN108420896A (en) * | 2017-02-14 | 2018-08-21 | 吴金霞 | Wind-expelling pain-stopping Huayu Tang |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101130055B (en) * | 2007-09-18 | 2010-06-02 | 江苏济川制药有限公司 | Method for producing medicament for treating headache |
| CN101773651A (en) * | 2010-04-19 | 2010-07-14 | 泰一和浦（北京）中医药研究院有限公司 | Chinese medicine composition for treating headache and preparation method thereof |
| CN102302751B (en) * | 2011-08-19 | 2013-06-19 | 周正山 | Chinese medicine for treating migraine |
-
2000
- 2000-01-27 CN CN 00110854 patent/CN1253201C/en not_active Expired - Fee Related
Cited By (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100345567C (en) * | 2006-01-17 | 2007-10-31 | 常效春 | Medicine for treating functional headache |
| CN101095900B (en) * | 2007-07-10 | 2010-11-10 | 黑龙江省中医研究院 | Sichuan chrysanthemum pain-relieving capsule and method for preparing the same |
| CN101167817B (en) * | 2007-10-20 | 2011-12-07 | 刘衍 | Traditional Chinese medicine for treating migraine |
| CN102145132A (en) * | 2011-03-13 | 2011-08-10 | 刘秀娥 | Traditional Chinese medicine for treating forehead pain |
| CN102342994B (en) * | 2011-10-18 | 2013-06-26 | 刘运波 | Traditional Chinese medicine for treating trigeminal neuralgia |
| CN102342994A (en) * | 2011-10-18 | 2012-02-08 | 文登市口腔医院 | Traditional Chinese medicine for treating trigeminal neuralgia |
| CN102641418A (en) * | 2012-05-14 | 2012-08-22 | 文庆贤 | Medicament for treating migraine |
| CN102727834A (en) * | 2012-07-18 | 2012-10-17 | 南京中医药大学 | Traditional Chinese medicine composition for treating migraine, and preparation method and application thereof |
| CN102727834B (en) * | 2012-07-18 | 2013-09-04 | 南京中医药大学 | Traditional Chinese medicine composition for treating migraine, and preparation method and application thereof |
| CN103272126A (en) * | 2013-05-30 | 2013-09-04 | 龙舟 | Traditional Chinese medicine for treating migraine |
| CN103263575A (en) * | 2013-06-01 | 2013-08-28 | 周留侠 | Medicine for treating headache and preparation method thereof |
| CN103330786A (en) * | 2013-07-11 | 2013-10-02 | 西华大学 | Medicinal composition for treating migraines, and preparation method thereof |
| CN103330786B (en) * | 2013-07-11 | 2015-06-17 | 西华大学 | Medicinal composition for treating migraines, and preparation method thereof |
| CN103385933A (en) * | 2013-07-19 | 2013-11-13 | 苏州市天灵中药饮片有限公司 | Catechu-containing traditional Chinese medicine preparation and preparation method thereof |
| CN103585596A (en) * | 2013-10-18 | 2014-02-19 | 程广金 | Traditional Chinese medicine composition for treating migraine |
| CN103585596B (en) * | 2013-10-18 | 2015-06-17 | 程广金 | Traditional Chinese medicine composition for treating migraine |
| CN103611129A (en) * | 2013-11-28 | 2014-03-05 | 秦雅昀 | Traditional Chinese medicine for treating neuropathic headache |
| CN103816367A (en) * | 2014-03-05 | 2014-05-28 | 济南伟传信息技术有限公司 | Traditional Chinese medicine for treating migraine |
| CN103920020A (en) * | 2014-04-15 | 2014-07-16 | 韩世昌 | Traditional Chinese medicine composition for treating headache and preparation method thereof |
| CN104383297A (en) * | 2014-10-30 | 2015-03-04 | 蔡炜 | Medicine for treating migraine |
| CN104435692A (en) * | 2014-12-19 | 2015-03-25 | 徐杨来 | Prescription for treating nerve headache and preparation method thereof |
| CN105233007A (en) * | 2015-10-30 | 2016-01-13 | 王志勇 | Traditional Chinese medicinal composition for treating migraine and preparation method of traditional Chinese medicinal composition |
| CN106511504A (en) * | 2016-12-20 | 2017-03-22 | 刘震 | Chinese patent medicine for conditioning migraine |
| CN108420896A (en) * | 2017-02-14 | 2018-08-21 | 吴金霞 | Wind-expelling pain-stopping Huayu Tang |
| CN107080787A (en) * | 2017-04-28 | 2017-08-22 | 吴冬梅 | Sedation-analgesia dissipates fiery soup |
| CN108159349A (en) * | 2018-01-17 | 2018-06-15 | 王芬 | A kind of Chinese medicine preparation for treating migraine and preparation method thereof |
| CN108096511A (en) * | 2018-01-24 | 2018-06-01 | 刘清 | A kind of Chinese medicine preparation and its manufacturing method of rapid recovery antimigraine |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1253201C (en) | 2006-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1253201C (en) | Medicine for treating hemicrania | |
| CN1390585A (en) | Chinese medicine for detoxication purpose and its preparing process | |
| CN103211990B (en) | Chinese medicinal composition for treating oral ulcer | |
| CN102335265A (en) | Chinese medicament for treating psoriasis | |
| CN106668508A (en) | Traditional Chinese medicine prescription for treating neurasthenia | |
| CN106110216A (en) | Treat neurasthenic Chinese medicinal formulae | |
| CN104667050B (en) | A kind of Chinese medicine for treating insomnia | |
| CN101024042A (en) | Medicine preparation for treating rheumatism disease by jointing Chinese medicine and western medicine | |
| CN105617042A (en) | Traditional Chinese medicine composition for treating headache | |
| CN1066954C (en) | Decoction for treatment of mental diseases | |
| CN100509013C (en) | Conditioning qi-invigorating weight-reducing extract | |
| CN105998559A (en) | Traditional Chinese medicine composition for treating Parkinson's disease | |
| CN101954018A (en) | Oral medicament for treating chronic nephritis | |
| CN1299748C (en) | Fat reducing regulating Qi supplement bag | |
| CN101912547B (en) | Medicament for treating dizziness and preparation method thereof | |
| CN103083613A (en) | Traditional Chinese medicine composition for treating migraine | |
| CN101045145A (en) | Health-care food for improving sexual function | |
| CN101444616B (en) | Medicated wine for curing chronic rheumatism and method for preparing same | |
| CN101181614B (en) | Medicament for curing podosoma numbness caused by cerebrovascular disease | |
| CN105833074A (en) | Traditional Chinese medicine composition for treating oral ulcer | |
| CN1739782A (en) | Health medicated wine for scraping sha-syndrome and cupping | |
| CN101041052A (en) | Chinese traditional medicine compound took orally for treating Raynand's disease | |
| CN1235840A (en) | Chinese medicine powder for curing rheumatoid and rheumatic diseases | |
| CN105169324A (en) | Chinese herba preparation for prevention and treatment of common cold due to wind-cold | |
| CN1151310A (en) | Oral liquid for treatment of heart disease and its prepn. method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |